WASHINGTON -- An investigational non-surgical treatment led to a "robust" complete response rate in patients with recurrent, low-grade non-muscle-invasive bladder cancer, the phase III ENVISION study ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...

Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. Background: The response to second-line therapies in patients failing BCG is generally very ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...

Zusduri is expected to be available on or around July 1, 2025. The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

Bladder cancer patterns of pelvic failure: Implications for adjuvant radiation therapy. Background: Combination chemotherapy is the standard of care for neoadjuvant, adjuvant, and metastatic bladder ...

In a recent randomized trial, electromotive intravesical administration of mitomycin before transurethral resection was shown to be effective in the prevention of bladder cancer recurrence. Although ...

Despite transurethral resection (TUR) and intravesical instillation of the most effective agents, a proportion of patients with transitional cell carcinoma of the bladder suffer a recurrence of their ...

The most common form of bladder cancer is transitional cell carcinoma (TCC). Non-muscle-invasive TCC is classified as stage Ta when the tumour is confined to the urothelium with no spread into the ...